Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

The Lancet Oncology

Volumn 18, Issue 1, 2017, Pages 100-111

  Takahashi, Koichi ^a,b   Wang, Feng ^a   Kantarjian, Hagop ^a   Doss, Denaha ^a   Khanna, Kanhav ^a   Thompson, Erika ^a   Zhao, Li ^a   Patel, Keyur ^a   Neelapu, Sattva ^a   Gumbs, Curtis ^a   Bueso Ramos, Carlos ^a   DiNardo, Courtney D ^a   Colla, Simona ^a   Ravandi, Farhad ^a   Zhang, Jianhua ^a   Huang, Xuelin ^a   Wu, Xifeng ^a   Samaniego, Felipe ^a   Garcia Manero, Guillermo ^a   Futreal, P Andrew ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IBRUTINIB; IFOSFAMIDE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PREDNISONE; RITUXIMAB; TEMOZOLOMIDE; VINBLASTINE; VINCRISTINE; VINORELBINE TARTRATE; TUMOR MARKER;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD; BONE MARROW TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; COLON ADENOCARCINOMA; CONTROLLED STUDY; DNA BARCODING; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GENE SEQUENCE; GLIOBLASTOMA; HEMATOPOIESIS; HODGKIN DISEASE; HUMAN; LUNG ADENOCARCINOMA; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MANTLE CELL LYMPHOMA; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; NON SMALL CELL LUNG CANCER; PENIS CANCER; PRIORITY JOURNAL; RECTUM CARCINOMA; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SMALL CELL LUNG CANCER; ADVERSE EFFECTS; CANCER STAGING; CELL CLONE; COMPARATIVE STUDY; GENETICS; HIGH THROUGHPUT SEQUENCING; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MULTIMODALITY CANCER THERAPY; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; TEXAS;

ADULT; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CLONE CELLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIESIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TEXAS;

EID: 85007426103     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30626-X     Document Type: Article

References (36)

1. 1 Leone, G, Pagano, L, Ben-Yehuda, D, Voso, MT, Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92 (2007), 1389–1398.
2. 2 Travis, LB, The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 15 (2006), 2020–2026.
3. 3 Smith, MR, Neuberg, D, Flinn, IW, et al. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood 118 (2011), 3525–3527.
4. 4 Leone, G, Fianchi, L, Pagano, L, Voso, MT, Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact 184 (2010), 39–45.
5. 5 Armitage, JO, Carbone, PP, Connors, JM, Levine, A, Bennett, JM, Kroll, S, Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 21 (2003), 897–906.
6. 6 Smith, SM, Le Beau, MM, Huo, D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102 (2003), 43–52.
7. 7 Kayser, S, Dohner, K, Krauter, J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117 (2011), 2137–2145.
8. 8 Abdelhameed, A, Pond, GR, Mitsakakis, N, et al. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Cancer 112 (2008), 1513–1521.
9. 9 Quintas-Cardama, A, Daver, N, Kim, H, et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 14 (2014), 401–410.
10. 10 Leone, G, Fianchi, L, Voso, MT, Therapy-related myeloid neoplasms. Curr Opin Oncol 23 (2011), 672–680.
11. 11 Morton, LM, Dores, GM, Tucker, MA, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975–2008. Blood 121 (2013), 2996–3004.
12. 12 Relling, MV, Boyett, JM, Blanco, JG, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101 (2003), 3862–3867.
13. 13 Lyman, GH, Dale, DC, Wolff, DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 28 (2010), 2914–2924.
14. 14 Krishnan, A, Bhatia, S, Slovak, ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 95 (2000), 1588–1593.
15. 15 Travis, LB, Holowaty, EJ, Bergfeldt, K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340 (1999), 351–357.
16. 16 Bhatia, S, Ramsay, NK, Steinbuch, M, et al. Malignant neoplasms following bone marrow transplantation. Blood 87 (1996), 3633–3639.
17. 17 Ding, Y, Sun, CL, Li, L, et al. Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: role of drug metabolism, apoptosis and DNA repair. Blood Cancer J, 2, 2012, e58.
18. 18 Felix, CA, Walker, AH, Lange, BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 95 (1998), 13176–13181.
19. 19 Larson, RA, Wang, Y, Banerjee, M, et al. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 94 (1999), 803–807.
20. 20 Sasai, Y, Horiike, S, Misawa, S, et al. Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia. Leuk Res 23 (1999), 975–981.
21. 21 Seedhouse, C, Faulkner, R, Ashraf, N, Das-Gupta, E, Russell, N, Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 10 (2004), 2675–2680.
22. 22 Li, L, Li, M, Sun, C, et al. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell 20 (2011), 591–605.
23. 23 Chakraborty, S, Sun, CL, Francisco, L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 27 (2009), 791–798.
24. 24 Busque, L, Patel, JP, Figueroa, ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 44 (2012), 1179–1181.
25. 25 Jaiswal, S, Fontanillas, P, Flannick, J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371 (2014), 2488–2498.
26. 26 Genovese, G, Kahler, AK, Handsaker, RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371 (2014), 2477–2487.
27. 27 Steensma, DP, Bejar, R, Jaiswal, S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126 (2015), 9–16.
28. 28 McKerrell, T, Park, N, Moreno, T, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep 10 (2015), 1239–1245.
29. 29 Xie, M, Lu, C, Wang, J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20 (2014), 1472–1478.
30. 30 Wong, TN, Ramsingh, G, Young, AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518 (2015), 552–555.
31. 31 Sarma, A, Rodriguez, MA, Cabanillas, F, et al. A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma. Proc Am Soc Clin Oncol, 22(suppl), 2004 abstr 8066.
32. 32 DiNardo, CD, Bannon, SA, Routbort, M, et al. Evaluation of patients and families with concern for predispositions to hematologic malignancies within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk 16 (2016), 417–428.
33. 33 Young, AL, Challen, GA, Birmann, BM, Druley, TE, Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun, 7, 2016, 12484.
34. 34 Bhatia, S, Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol 40 (2013), 666–675.
35. 35 Bondar, T, Medzhitov, R, p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell 6 (2010), 309–322.
36. 36 Marusyk, A, Porter, CC, Zaberezhnyy, V, DeGregori, J, Irradiation selects for p53-deficient hematopoietic progenitors. PLoS Biol, 8, 2010, e1000324.